CXXC4 Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA521054-Each-of-1 | In Stock | ₹ 46,591.50 |
PIPA521054 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 46,591.50
GST (18%): ₹ 8,386.47
Total Price: ₹ 54,977.97
Antigen
CXXC4
Classification
Polyclonal
Conjugate
Unconjugated
Gene
CXXC4
Gene Alias
9330210J02Rik; C030003J12Rik; CXXC finger 4; CXXC finger protein 4; CXXC4; CXXC-type zinc finger protein 4; Dvl-binding protein IDAX (inhibition of the Dvl and Axin complex); Idax; inhibition of the Dvl and axin complex protein; inhibitor of the Dvl and Axin complex
Host Species
Rabbit
Purification Method
Antigen affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
319478, 80319, 83824
Content And Storage
Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C
Form
Liquid
Applications
Immunohistochemistry, Western Blot
Concentration
1 mg/mL
Formulation
PBS with 0.02% sodium azide
Gene Accession No.
Q6NXI8, Q9EQC9, Q9H2H0
Gene Symbols
CXXC4
Immunogen
An 18 amino acid peptide near the amino terminus of human CXXC4.
Quantity
100 μg
Primary or Secondary
Primary
Target Species
Human, Mouse, Rat
Product Type
Antibody
Isotype
IgG
Related Products
Description
- A suggested positive control is human brain tissue lysate
- PA5-21054 can be used with blocking peptide PEP-1168
- CXXC4 is zinc finger protein that binds directly to the PDZ domain of DVL1, a protein involved in the Wnt signaling pathway, through its C-terminal region
- CXXC4 interaction with DVL1 competes with DVL1-AXIN binding, although the affinity of DVL1 for CXXC4 is lower than that for AXIN
- In mouse fibroblasts, CXXC4 suppressed Wnt3a induction of beta-catenin and inhibited Wnt3a-dependent TCF4 activation, suggesting that CXXC4 acts as a negative regulator of the Wnt signaling pathway and functions between DVL and beta-catenin
- Recent reports suggest that decreased CXXC4 expression is associated with kidney cancer metastasis, cell proliferation, reduced apoptosis in response to cancer drugs, and upregulation of genes involved with proliferation, invasion and cell survival, suggesting that CXXC4 plays a critical role in tumor progression in kidney cancer.